An Immunobridging study to evaluate the neutralizing antibody titer in adults immunized with two doses of either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
View ORCID ProfileJosue Antonio Estrada, Chien-Yu Cheng, Shin-Yen Ku, Hui-Chun Hu, Hsiu-Wen Yeh, Yi-Chun Lin, Cheng-Pin Chen, Shu-Hsing Cheng, I-Feng Lin
doi: https://doi.org/10.1101/2022.02.26.22271364
Josue Antonio Estrada
1Medigen Vaccine Biologics, Taipei, Taiwan
Chien-Yu Cheng
2Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
3Institute of Public Health, School of Medicine National Yang-Ming Chiao Tung University
Shin-Yen Ku
4Department of Nursing, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
Hui-Chun Hu
4Department of Nursing, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
Hsiu-Wen Yeh
4Department of Nursing, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
Yi-Chun Lin
2Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
Cheng-Pin Chen
2Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
5School of Clinical Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan
Shu-Hsing Cheng
2Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan
6School of Public Health, Taipei Medical University, Taipei, Taiwan
I-Feng Lin
3Institute of Public Health, School of Medicine National Yang-Ming Chiao Tung University
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
All data produced in the study are available upon reasonable request to the authors
Posted March 01, 2022.
An Immunobridging study to evaluate the neutralizing antibody titer in adults immunized with two doses of either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
Josue Antonio Estrada, Chien-Yu Cheng, Shin-Yen Ku, Hui-Chun Hu, Hsiu-Wen Yeh, Yi-Chun Lin, Cheng-Pin Chen, Shu-Hsing Cheng, I-Feng Lin
medRxiv 2022.02.26.22271364; doi: https://doi.org/10.1101/2022.02.26.22271364
An Immunobridging study to evaluate the neutralizing antibody titer in adults immunized with two doses of either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
Josue Antonio Estrada, Chien-Yu Cheng, Shin-Yen Ku, Hui-Chun Hu, Hsiu-Wen Yeh, Yi-Chun Lin, Cheng-Pin Chen, Shu-Hsing Cheng, I-Feng Lin
medRxiv 2022.02.26.22271364; doi: https://doi.org/10.1101/2022.02.26.22271364
Subject Area
Subject Areas
- Addiction Medicine (347)
- Allergy and Immunology (666)
- Anesthesia (181)
- Cardiovascular Medicine (2642)
- Dermatology (223)
- Emergency Medicine (398)
- Epidemiology (12213)
- Forensic Medicine (10)
- Gastroenterology (758)
- Genetic and Genomic Medicine (4089)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2650)
- Health Policy (1004)
- Hematology (362)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (433)
- Neurology (3866)
- Nursing (209)
- Nutrition (577)
- Oncology (2025)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (304)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (472)
- Pediatrics (1113)
- Primary Care Research (450)
- Public and Global Health (6518)
- Radiology and Imaging (1399)
- Respiratory Medicine (871)
- Rheumatology (406)
- Sports Medicine (342)
- Surgery (446)
- Toxicology (53)
- Transplantation (185)
- Urology (165)